Indian pharma and healthcare companies anticipate improved revenue and profit in the June 2025 quarter, fueled by domestic market growth. However, US pricing pressure, particularly for Revlimid generics, may impact some firms. Hospital chains are poised for better performance due to increased operational beds, while individual companies like Lupin expect strong US growth and margin expansion.
